All In Biotech

Drug Trial Radar · NCT00293319

131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma

I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma, A Phase II Study

Last checked: Nov 20, 2026Latest source record: Aug 18, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

164

Actual

Start

Apr 2005

Primary completion

Mar 2006

Study completion Mar 2006

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Feb 17, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Radioactive drugs, such as 131 I-MIBG, may carry radiation directly to tumor cells and not harm normal cells. PURPOSE: This phase II trial is studying how well 131 I-MIBG works in treating patients with refractory or relapsed neuroblastoma.

Conditions

  • Neuroblastoma

Interventions

  • filgrastimBiological

  • iobenguane I 131Radiation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ability of iodine I 131 metaiodobenzylguanidine to provide palliative therapy
  2. Acute and late toxicities

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • UCSF Comprehensive Cancer Center

    San Francisco, California

  • University of Michigan Comprehensive Cancer Center

    Ann Arbor, Michigan

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.